Pipeline
Focused on the Retina
Our pipeline is focused on tackling the leading causes of blindness, beginning with wet AMD*.
| Program | Therapeutic Focus | Preclinical | Early Clinical Stage (Phase 1) | Mid Clinical Stage (Phase 2) | Registrational Clinical Stage (Phase 3) | FDA Approval | ||
|---|---|---|---|---|---|---|---|---|
|
Program
|
Therapeutic Focus
Wet AMD*
|
Preclinical
|
Early Clinical Stage (Phase 1)
|
Mid Clinical Stage (Phase 2)
|
Registrational Clinical Stage (Phase 3)
|
|
||
|
Program
|
Therapeutic Focus
NPDR†
|
Preclinical
|
Early Clinical Stage (Phase 1)
|
|
|
|
||
|
Program
|
Therapeutic Focus
Glaucoma and ocular hypertension
|
Preclinical
|
Early Clinical Stage (Phase 1)
|
Mid Clinical Stage (Phase 2)
|
|
|
* Age-related Macular Degeneration (AMD)
† Non-proliferative Diabetic Retinopathy (NPDR)
Caution: All investigational product candidates are currently undergoing clinical evaluation. This chart is not intended to convey any conclusion of safety or efficacy, and there is no guarantee that any product candidate will successfully complete development or gain FDA approval.
Our Technology
ELUTYX™
Our ELUTYX technology is a versatile platform employed to create sustained-release therapies that may expand treatment options across multiple ocular conditions.
CLINICAL TRIALS
